- Home
- MAKO vs STTK Comparison
MAKO vs STTK Comparison
Compare MAKO & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MAKO | STTK |
|---|---|---|
| Founded | N/A | 2016 |
| Country | Canada | United States |
| Employees | 30 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 861.6M | 792.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | MAKO | STTK |
|---|---|---|
| Price | $10.21 | $6.64 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 179.1K | ★ 764.7K |
| Earning Date | N/A | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.58 | $1.68 |
| 52 Week High | $11.10 | $8.33 |
Technical Indicators
Market Signals| Indicator | MAKO | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 57.66 | 39.85 |
| Support Level | $9.42 | $6.56 |
| Resistance Level | $10.28 | $6.81 |
| Average True Range (ATR) | 0.44 | 0.34 |
| MACD | -0.13 | -0.13 |
| Stochastic Oscillator | 46.58 | 8.38 |
Price Performance
Historical ComparisonAbout MAKO Mako Mining Corp Common Stock
Mako Mining Corp is a gold mining, development, and exploration firm. The companies primary asset is the San Albino mine, an open-pit mine located in Nicaragua. In addition to its mining operation, the company continues to explore its other concessions in Nicaragua and Guyana.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.